Kala enters agreement to sell Eysuvis, Inveltys to Alcon

Kala Pharmaceuticals has entered into a definitive agreement to sell its commercial portfolio and related assets to Alcon, including Eysuvis and Inveltys.
Kala is to receive a $60 million upfront payment with additional sales-based milestone payments, according to a press release.
Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%) is approved for the short-term treatment of the signs and symptoms of dry eye, and Inveltys (loteprednol etabonate ophthalmic suspension 1%) is a twice-daily corticosteroid treatment for postoperative pain and inflammation following ocular surgery.
“The

Kala Pharmaceuticals has entered into a definitive agreement to sell its commercial portfolio and related assets to Alcon, including Eysuvis and Inveltys.
Kala is to receive a $60 million upfront payment with additional sales-based milestone payments, according to a press release.
Eysuvis (loteprednol etabonate ophthalmic suspension 0.25%) is approved for the short-term treatment of the signs and symptoms of dry eye, and Inveltys (loteprednol etabonate ophthalmic suspension 1%) is a twice-daily corticosteroid treatment for postoperative pain and inflammation following ocular surgery.
“The